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Abstract
Background: Intimate partner violence (IPV) has important impacts on the health of women in society. Our aim
was to estimate the health and economic benefits of reducing the prevalence of IPV in the 2008 Australian female
adult population.
Methods: Simulation models were developed to show the effect of a 5 percentage point absolute feasible
reduction target in the prevalence of IPV from current Australian levels (27 %). IPV is not measured in national
surveys. Levels of psychological distress were used as a proxy for exposure to IPVsince psychological conditions
represent three-quarters of the disease burden from IPV. Lifetime cohort health benefits for females were estimated
as fewer incident cases of violence-related disease and injury; deaths; and Disability Adjusted Life Years (DALYs).
Opportunity cost savings were estimated for the health sector, paid and unpaid production and leisure from
reduced incidence of IPV-related disease and deaths. Workforce production gains were estimated by comparing
surveyed participation and absenteeism ratesof femaleswith moderate psychological distress(lifetime IPVexposure)
against high or very high distress(current IPVexposure), and valued using the friction cost approach (FCA). The impact
of improved health statuson unpaid household production and leisure time were modelled from time use survey data.
Potential costsassociated with interventions to reduce IPVwere not considered. Multivariable uncertainty analysesand
univariable sensitivity analyseswere undertaken.
Results: A 5 percentage point absolute reduction in the lifetime prevalence of IPVin the 2008 Australian female
population wasestimated to produce 6000 fewer incident casesof disease/injury, 74 fewer deaths, 5000 fewer DALYs
lost and provide gainsof 926,000 working days, 371,000 daysof home-based production and 428,000 leisure days.
Overall, AUD371 million in opportunity cost savingscould be achievable.The greatest economic savingswould be
home-based production (AUD147 million), followed by leisure time (AUD98 million), workforce production
(AUD94 million) and reduced health sector costs (AUD38 million).
Conclusions: Thisstudy contributesnew knowledge about the economic impact of IPVin females. The findings
provide evidence of large potential opportunity cost savingsfrom reducing the prevalence of IPVand reinforce the
need to reduce IPVin Australia, and elsewhere.
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Background
Intimate partner violence (IPV) is an important global
public health problem. It was ranked 23rd in terms of
Disability Adjusted Life Years (DALYs) arising in women
in the most recent update of the Global Burden of Disease
(GBD) Study 2010, following after other important risk
factors such as high total cholesterol, suboptimal
breastfeeding, alcohol use, physical inactivity, high blood
pressure and dietary risks [1].
Globally, IPV is a major public health concern because it
is the most common form of violence that women experi-
ence [2]. IPV has been defined for an international survey
as women who had a current or former intimate partner
and had experienced violence from that partner during
their lifetime [3]. Alternate terminologies include domestic
violence, family violence or relationship violence. IPV refers
to violence occurring between people who are, or were
formerly, in an intimate relationship and were subject to
economic, psychological or emotional abuse through to
physical and sexual violence [4].
There have been several attempts to make meaningful
cross-country comparisons in rates of IPV [2, 5–10]. One
of the most comprehensive (including past and current
exposure) to compare rates of IPV across countries was the
International Violence Against Women Survey (IVAWS).
One of the main aims of the IVAWS was to facilitate inter-
national comparisons by using standardised measurement
tools and techniques to establish prevalence in each
participating country. Johnson et al. [3] reported data for
Australia and eight other countries. Prevalence of IPV was
highest in Mozambique (40 %) and lowest in Hong Kong
(9 %), with other countries in between: Czech Republic
(37 %), Costa Rica (36 %), Australia (27 %), Denmark
(22 %), Poland (16 %), Philippines (10 %) and Switzerland
(10 %) [3]. In 2010, Devries and colleagues estimated
women’s lifetime prevalence of IPV for 21 regions [2].
Globally, 30 % of women aged 15 and over were reported
to have experienced IPV during their lifetime. In this latter
study, the greatest prevalence of IPV was found in Cen-
tral Sub-Saharan Africa (66 %) and lowest in East Asia
(16 %), while, Australasia had an IPV prevalence of 28 %
[2]. In the most recent personal safety survey for Australia,
17 % of women surveyed in 2012 had experienced IPV
since the age of 15 [11]. In Victoria (Australia), IPV con-
tributes 3 %to the total disease burden and 8 % in women
aged 15–44 [4]. In this younger age group, it is the leading
contributor to death and disability, being responsible for
more disease burden than other well-known risk factors,
such as high blood pressure, smoking and obesity [4].
Recognizing its importance on health and production
consequences, the prevention of IPV should be a priority
in all countries [12]. A reduction in prevalence of IPV can
have important impacts on society, including en-
hanced psychological well-being, which at a population
level improves general health and productivity. Quantifying
the economic impact of IPV is also important, since it
demonstrates the extent of these societal impacts.
However, few studies of the costs of IPV have been
undertaken, and the methods used vary since the research
questions also differ e.g. including impacts of IPV on both
men and women, including a larger range of indirect or
intangible costs such as counting the costs to future
generations, costs of pain and suffering, consumption
related costs, or transfer costs [5]. This means that these
studies are generally incomparable due to the different
definitions and assumptions applied (including the time
horizon for counting the costs), limiting the ability to
compare the economic implications of IPV with other
important conditions. Previous costing studies in Australia
have found IPV was responsible for increased costs to the
community between AUD8.1 billion and AUD9.9 billion
(2007–08 dollars) annually [5, 13] and was predicted to
grow to AUD15.6 billion by 2021–22 if no action is taken
[13]. These earlier studies provide estimates of the total
economic costs that could be avoided if the violence
was to be eliminated, rather than estimating the extent of
societal benefits if the prevalence of IPV against females
was to be reduced by a feasible amount.
The aim of this study was to separately quantify the
health and economic benefits within the paid and unpaid
production sectors and health sector that could be
achieved following a feasible reduction (as opposed to a
complete elimination) of IPV in the Australian female
adult population. This study on IPV was part of a larger
study funded by the Victorian Health Promotion
Foundation (VicHealth) whereby the benefits of feasible
reductions in the prevalence of long term harmful alcohol
consumption, physical inactivity, high body mass index,
tobacco smoking, inadequate consumption of fruit and
vegetables, and IPV were estimated using a standardized
approach [14]. Therefore, the advantage of our study in
relation to prior research in this field is that we can
reliably put the findings for IPV within a broader policy
context. This is because we highlight not just the total at-
tributable burden based on the aspects we have measured,
but also what could be gained if a realistic absolute reduc-
tion in IPV prevalence could be achieved.
Methods
Relevant diseases and injuries associated with IPV include
depression, anxiety, cancer, chronic obstructive pulmonary
disease (COPD), and suicide [15, 16]. To estimate the
health and economic benefits to society of reducing the
prevalence of IPV, the impact of an absolute reduction in
the prevalence of IPV levels for the 2008 Australian
female population was calculated. This was quantified as
reduced: a) incident cases of preventable IPV-related
diseases/injuries; b) deaths; and c) disability adjusted life
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years (DALYs). We simulated benefits of risk factor preva-
lence reductions for this one reference year. However, the
time horizon for benefits estimation was based on a life-
time perspective for that 2008 female population cohort.
The selected feasible prevalence reduction targets for IPV
in Australia were based on consensus by an expert Advisory
Committee who were presented with a review of the litera-
ture. Since the literature on prevention interventions did not
include readily usable estimates for feasible reductions,
prevalence rates of IPV from other countries were consulted.
Comparing prevalence rates in Australia to other
countries provides indirect evidence of possible achiev-
able prevalence levels from a country with a broadly
comparable social, demographic and economic profile
[14]. The feasible reductions could then be modelled
against attainment of lower prevalence levels of IPV as ob-
served in a comparable country to Australia (referred to
as an ‘Arcadian’ normal [17]). However, comparing
across countries posed some difficulties since some
prevalence estimates were based on all women, others
based on only those women who have ever had a
partner, and others based on women who currently
have a partner. Furthermore, the definition of an ‘intim-
ate partner’ (husband, de facto, cohabiting partner, boy-
friend, etc.) and the definition of what constitutes violence
differs across studies. Using data from the IVAWS study
overcame many of these issues [3]. However, we acknow-
ledge that in this study there were important differences
between participating countries, including sample size,
age distribution of respondents, response rate and method
of interview. Among the countries with lower prevalence
estimates than Australia, Poland, Philippines and
Hong Kong were ruled out as comparators for being
socio-culturally different. Although broadly comparable,
Switzerland had a prevalence of only 10 % which seemed
remarkably low, and was considered by the Advisory
Committee too ambitious a target for Australia to achieve
in the short term. Denmark, with a prevalence of 22 %,
was selected as the most appropriate Arcadian comparator.
The Advisory Committee agreed that there was the
potential to reduce IPV prevalence in Australia by up
to 5 percentage points, shifting the estimated current
prevalence of 27 % to 22 %. A 5 percentage point absolute
reduction in IPV was selected as an ideal feasible target
(22 %), with a progressive target of 24.5 %also assessed.
Past and current exposure to IPV is most influential in
determining the current health burden, health sector
costs and production and leisure costs, but past exposure
is not amenable to prevention efforts. The effects of past
exposure can only be ameliorated through current health
services. It is current levels of IPV that are amenable to
preventive interventions and, thus gradually over time, the
lifetime prevalence of IPV can be expected to fall. If a
woman ceases to be exposed to current IPV, we have
modelled that she will change from a high level of psycho-
logical distress to a moderate level, since she remains
exposed to lifetime (past) IPV.
Data sources for simulation models
The most relevant Australian data sources for our reference
year 2008 were used. The current estimates for the lifetime
prevalence of IPV by age for females were based on the
2003 Burden of Disease incidence and deaths data because
these were the most current data available at the time
this study was undertaken. Population Attributable Risk
Fractions (PAFs), and DALYs were also obtained using
the 2003 Australian Burden of Disease data files [16]
made available for this study. The definition for IPV in
the 2003 Burden of Disease study was based on two cat-
egories of exposure to IPV, which included physical or
sexual violence by a partner in the last 12 months, and
physical or sexual violence by a partner more than
12 months ago. This was estimated, using information from
the Women’s Safety Survey data reported by the Australian
Bureau of Statistics (ABS), to determine the prevalence of
‘IPV without child sexual abuse’ and ‘child sexual abuse and
IPV combined’ where an adjusted relative risk to account
for the combined exposure state of having experienced both
child sexual abuse and intimate partner violence was used
[16]. Begg et al. only provided estimates for females due to
insufficient evidence on prevalence and risk among males.
Since the Australian National Health Survey (NHS)
2004–05 does not measure IPV directly, we used levels of
psychological distress as a proxy for exposure to IPV. This
is because psychological conditions including depression
and anxiety, as well as suicide and self-inflicted harm con-
tribute most (74 %) of the disease and injury burden associ-
ated with IPV [18]. The population groups compared were
the female Australian population reporting high or very
high levels of psychological distress (score 22–50 on the
Kessler Psychological Distress Scale −10), and the females
reporting moderate levels of distress (score 10–21)
[19, 20]. We used the proxy distress levels to isolate
workforce behaviours (workforce participation, absentee-
ism and days out of role), since females with diagnosed
depression and anxiety were not identified in the NHS.
Demographic data, employment status, and health-related
actions of females in the comparator groups were also
obtained from the 2004–05 NHS dataset (Table 1).
The 2000–01 Disease Costs and Impact Study Excel
files, which adopted the Burden of Disease classification
system, were used to estimate the change in health
sector costs from reduced incidence of disease and injuries
associated with IPV [21, 22]. Household production and
leisure time were derived from the 2006 ABS Time Use
Survey [23]. Current average wages for 2008 were sourced
from the ABS and published government pay scale sum-
maries [24, 25].
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Data analyses
Details of the simulation models used in the current study
have been published in detail elsewhere [14, 26–28].
Briefly, the net differences in mortality, incident morbidity
and consequent health sector costs and the impacts on
paid and unpaid production and leisure between the
current prevalence of IPV and the two target prevalence
levels for the 2008 Australian female adult population
were estimated with population-based simulation models
developed in Excel (Microsoft Corporation, 2003). Cost
data from other years were adjusted to 2008 Australian
dollars (AUD) by applying health price inflators [29]. For
readers wishing to convert AUD in 2008 to US dollars in
2008, the purchasing power parity of AUD1.48 should be
used [30]. A 3 %discount rate for lifetime benefits was ap-
plied [31], and varied in sensitivity analyses using 0, 5 and
7 %(data not reported but available from the authors).
To estimate changes in hea lth sector costs, the attrib-
utable portion of total health sector costs to disease and
injuries associated with IPV were estimated using PAFs
for diseases and injuries attributable to IPV for females by
age group [16]. The modelling of lifetime health expend-
iture cost savings from these data was estimated by
assuming the annual health sector costs of treating
incident and prevalent cases of disease attributable to
IPV approximates the life time health sector cost savings of
a reduction in the incident cases of IPV for our reference
(2008) population.
If a target reduction in IPV prevalence was achieved,
the production ga ins/ losses and ta xa tion effects in the
Australian economy were modelled by the simulation of
a theoretical cohort of Australian women (ages 15–65
years) during their working years until retirement age
[14]. Briefly, the working lifetime income earned and
taxation paid by females were calculated taking into ac-
count known participation rates and absenteeism rates by
age of the exposed (high distress) and the comparator
(moderate distress) populations and average female wage
rates. The production gains or losses arise from changes in
income earned and taxation paid that result from fewer
deaths and incident cases of disease and injury, associ-
ated with the reduction in prevalence of IPV in the female
adult population. In a separate sensitivity analysis, unisex
average wage rates were applied to the total female popula-
tion (analysis available from the authors).
Two methodological techniques were used to value
the production gains or losses. First, the Friction Cost
Approach (FCA) was used where it was assumed that
individuals who die or leave the workforce due to disability
would be replaced after a specified friction period; we used
3 months and varied this to 6 months in a sensitivity ana-
lysis. The second valuation technique of Human Capital
Approach (HCA) was used to value workforce production
gains or losses. The HCA counts as lost all the future
income up to age 65 from an individual who leaves
the workforce due to death or disability. There remains
Table 1 Demographics and days of high psychological distress due to ill health by age, sex and work force status for the 2008
female adult Australian population
Females High or very high distress Moderate distress
Age summary
Age 15–64 y 989,848 1,636,652
N (95 % CI) (927,959–1,051,738) (1,556,018–1,717,285)
Age 65+ y 153,190 300,836
N (95 % CI) (132,009–174,372) (265,299–336,372)
Age 15+ y 43.8 43.5
Mean (95 % CI) (42.7– 44.9) (42.8– 44.2)
In Labour Force (15+ years)a
% (95 % CI) 53 % (50–57 %) 62 % (59–64 %)
Mean days off work (95 % CI) 0.69 (0.52–0.85) 0.28 (0.21–0.35)
Not in Labour Force
% (95 % CI) 47 % (43–50 %) 39 % (36–41 %)
Mean days of reduced activity: 15–64 y (95 % CI) 3.03 (2.54–3.53) 1.47 (1.15–1.79)
Aged 65+ years
% (95 % CI) 13.4 % (11.7–15.3 %) 15.5 % (13.9–17.3 %)
Mean days of reduced activity (95 % CI) 3.62 (2.70–4.55) 2.25 (1.75–2.75)
Source: National Health Survey 2004–05 (ABS, 2006). Mean days measured over a two week period
CI confidence interval, N number
aincludes unemployed seeking work and 65+ years
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debate in the economic literature about which method is
preferable [32, 33] since they give such divergent results
and measure different constructs. The HCA measures the
potential productive value of a human life, whereas the
FCA measures the shorter term losses faced by business
and individuals when an unplanned departure from the
workforce occurs. For the purposes of the current study,
the FCA provided a stronger logical connection to
the actual likely cost impact of premature death or
disability associated with IPV on industry and thus
only FCA results are presented in this paper [14].
The economic value of hours of lost leisure and house-
hold production associated with diseases attributable to
IPV was estimated using a separate ‘Household Produc-
tion and Leisure Time’ model [14]. The NHS 2004–05
provided self-reported days out of role for the exposed
(very high to high distress) and comparator (moderate
distress) Australian women. The net difference in the
value of the days out of household production and leisure
time between the comparator groups was counted as the
potential economic gain. Impacts on both working and
non-working women by age were estimated and household
production was defined as the hours spent performing
non-paid household duties such as cooking, shopping,
cleaning, child care and maintenance. These were valued
at ‘replacement cost’ using the average 2008 market based
wage rates for domestic services and child care. Leisure
time comprised social and community interaction, together
with recreation and leisure activities only and was valued
using the ‘opportunity cost method’, applying one third of
the average female 2008 weekly earnings [24].
Uncertainty analyses
Multivariable probabilistic uncertainty analyses were
undertaken using @RISK software version 4.5 for Excel
(Palisade Corporation, Ithaca, New York 2005). Input
variables were modelled as known distributions rather
than single values where uncertainty existed (e.g. each
surveyed parameter and life-years remaining). Uncertainty
in wages, participation rates and absenteeism were cap-
tured in the reported survey standard errors [19, 25, 34].
Uncertainty in health outcomes was not incorporated
directly, because the reported 2003 DALY estimates attrib-
utable to IPV included no uncertainty ranges. Instead we
relied on varying the absolute IPV prevalence reduction in
a sensitivity analysis to convey variability around improved
health outcomes. The range of values that were simulated
as part of uncertainty and sensitivity analyses are available
in an additional file. In this Additional file 1: Table S1 con-
tains the input values (average, low and high) of child care,
domestic services and average weekly earnings used to esti-
mate household production and leisure time costs and
Table S2 provides a summary of input parameters and un-
certainty ranges for the economic models and contains
detail of the sources, values, uncertainty distributions and
detailed comments relevant to all data inputs used in the
modelling see Additional file 1: Table S1 and S2. For
example, we varied work force participation rates, absen-
teeism rates, average weekly earnings, days worked in a
year, days of reduced activity due to ill health and years of
remaining life expectancy as part of these analyses. Monte
Carlo sampling with minimum 4000 simulations were
used to estimate a mean and 95 % uncertainty inter-
val for the outcome parameters.
Results
The demographic data and days of reduced activity for
females with moderate psychological distress and high
or very high distress by age and workforce status are
presented in Table 1. Females with high or very high
distress participated less in the workforce than females
with moderate distress (Fig. 1). The females with high or
very high distress in the workforce, took more days off
work compared with females with moderate distress. In
addition, females with high or very high distress not in the
workforce or past retirement age had more days of reduced
activity compared to females with moderate distress.
If the prevalence of IPV in the adult Australian popula-
tion was reduced by 5 percentage points, the estimated
34,000 annual new cases of IPV-related disease could be
reduced by 6000 (18 %); the 440 annual deaths attributed
to IPV could be reduced by 74 deaths (17 %); and the esti-
mated 29,000 DALYs attributed to IPVcould be reduced by
about 5000 (17 %) (Table 2). Nearly half of these benefits
would arise if a 2.5 percentage point progressive absolute
reduction in prevalence target was achieved.
The estimated health and economic benefits from re-
duced IPV resulted in total potential opportunity cost
savings of AUD377 million, which is comprised of AUD38
million to the health sector (19 % of IPV attributable
annual health sector costs), AUD94 million in workforce
production (FCA), AUD98 million in leisure based pro-
duction and AUD147 million in home based production
(Table 3). The latter production costs represent approxi-
mately 18 % of the total attributable to this risk factor
(AUD1,801 million). The largest component of these total
potential opportunity cost savings would occur in house-
hold production and leisure (Fig. 2).
Discussion
The primary finding of this study is that a feasible 5
percentage point absolute reduction in prevalence of
IPV can lead to total potential opportunity cost savings of
AUD377 million, with only 10 % of the savings arising in
the health sector. The largest potential saving from re-
duced lifetime prevalence of IPV in the female population
will occur in home based production, followed by leisure,
and workforce production. These savings would be much
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larger (approx. AUD2 billion) if IPV was able to be totally
eliminated from Australia (AUD207 million in health
sector, AUD1,801 million [FCA] in production and leisure).
However, our aim was to identify savings that were realistic
and relevant to the setting of future public health
campaigns focusing on risk factor reduction strategies.
An important aspect of the present study was the
separate identification of benefits across workforce,
household production and leisure time associated with
reduced IPV. Earlier studies that have not accounted
for home-based and leisure production underestimate
potential savings in the context of IPV prevention.
While the current methodology does identify the con-
tribution of household production and leisure, it is
conservative since it excludes an assessment of the
additional time available for household and leisure
Fig. 1 Workforce participation rates of women with high levels of psychological distress compared to women with moderate levels of distress by
age. Source: adapted from data obtained from National Health Survey 2004–05 [19]
Table 2 Health status and production effects from reducing the prevalence of intimate partner violence
Benefit Feasible 5 percentage point absolute prevalence reduction target
95 % uncertainty interval
Mean (‘000 s) Lower Limit (‘000 s) Upper Limit (‘000 s)
Disability adjusted life years 5 n/a n/a
Incidence of intimate partner violence related disease 6 n/a n/a
Mortality 0.07 n/a n/a
Lifetime
Leisure (days) 428 296 568
Absenteeism (days) 926 n/a n/a
Days out of home based production role (days) 371 259 491
Early retirement (persons) 0.52 n/a n/a
Incidence of disease and mortality calculated for all age groups. Leisure and home based production calculated for persons aged 15+ years. Absenteeism and
early retirement calculated for persons aged 15–64 years. All estimates uncorrected for potential joint effects of multiple risk factors. Note the result for
absenteeism has been updated since in the Full Technical Report this figure had not been discounted and was incorrect (http://www.vichealth.vic.gov.au/
~/media/ResourceCentre/PublicationsandResources/Knowledge/Research%20Report_FINAL_July09.ashx, last accessed 13 June 2015)
n/a, not available, unable to be estimated based on the data that were available
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tasks, which the cohort of the working age 2008 female
population will have following retirement, through their
remaining life expectancy.
We are able to compare results of reducing IPV with five
other risk factors assessed using the same methodology
and data sources [14]. We found that the total economic
benefit of reducing IPV was ranked third behind gains
following reductions in high risk alcohol consumption
and tobacco consumption. This is jointly explained by the
different reduction targets deemed feasible for each
respective risk factor, the distribution of the population
exposure to the risk factors across age groups and sexes as
well as the disease and injuries associated with risk factors.
While we recognise a potential equity issue by applying
lower average wage rates for females compared with
males, we were able to test its impact in sensitivity ana-
lysis. Adopting annual average unisex wages increased the
overall estimates IPV gains by AUD25 million. However if
Table 3 Economic outcomes from reducing the prevalence of intimate partner violence
Economic outcomes Feasible reduction targeta
95 % uncertainty interval
Mean (AUD million) Lower limit (AUD million) Upper limit (AUD million)
Health sector costs 38 n/a n/a
Production Costs FCA 88 29 185
Recruitment and training costs 6 n/a n/a
Taxation effects FCAb 16 4 36
Leisure based production 98 61 144
Home based production 147 102 195
Total production FCAc 377 227 461
Sensitivity analysis
Production Costs HCA 434 253 621
Taxation effects HCAb 57 29 87
Total production HCAc 678 480 884
All estimates uncorrected for joint effects of the presence of multiple risk factors in individuals. Health sector, leisure and home based production based on
females 15+ years. Production, recruitment and training and taxation effects based on females 15–64 years
HCA human capital approach, FCA friction cost approach (preferred conservative estimate), n/a not available, unable to be estimated based on the data that
were available
aThese are not estimates of immediately realizable cash savings
bTaxation is treated as a transfer payment and should not be added to production effects
cTotal production is the sum of workforce production costs, household- and leisure-based production
Fig. 2 Proportion of opportunity cost savings from reductions in various risk factors by economic category
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we had analysed and reported all the risk factors with
unisex wage rates, the relative ranking of the gains
through a feasible reducing IPV would still rank third
behind the gains following feasible reductions in alcohol
consumption and tobacco use.
The distribution of opportunity cost savings differs for
IPV relative to other risk factors we have evaluated using
the same methodology and data sources [14]. For all
others, the savings in the health sector represent the larger
proportion of total savings (Fig. 2). Health sector cost
savings due to reduced prevalence of IPV were only found
to be 10 % of the total savings. In all other risk factors we
evaluated (except physical inactivity), the opportunity cost
savings to the health sector were as high as the productivity
and leisure costs, if not two to three times greater [14].
This arises primarily due to four main reasons: (i) the ben-
efits of reducing IPV apply mostly to the subset of females
who are providing the child bearing and child raising roles
during their productive years; (ii) there are disproportion-
ately lower rates of treatment of mental illness associated
with IPV compared to physical impacts of cancers and
heart disease associated with other major risk factors, (iii)
only 41 % of women with any mental health problem
(assessed as lifetime prevalence and 12 months symptoms
prior to the survey date) sought help for their mental
health problem as reported in the most recent National
Mental Health Survey [35]; and (iv) a General Practitioner
was likely to be the service provider most frequently
sought by females with a mental health problem, hence
there is an absence of expensive hospital costs in the
treatment of anxiety disorders and depression [35].
Comparisons with other IPV research in this field are
difficult because of differences in methods, assumptions,
populations included and the scope of the costs analyzed.
However, earlier assessment of the costs of domestic
violence in Australia also highlighted that household,
leisure and production impacts are where the greatest
costs attributable to IPV may be found [5].
Our estimates are very conservative in comparison to
other studies where estimates of potential cost savings to
future generations of children in families experiencing
domestic violence are included. In the studies reported
by Access Economic [5] and KPMG, second generation
costs of AUD28 million were to be expected from a
10 % reduction in IPV prevalence [13]. This category in-
cludes short-term costs of providing protection and
other services (such as child protection services, child-
care and remedial/special education) to children of rela-
tionships where there is domestic violence, and longer-
term costs imposed on society by these children as they
grow older (such as increased crime and future use of
government services). Our estimates, which take a nar-
rower perspective and address realistic reductions in
prevalence, are an underestimate of total current and
future generation societal costs. In addition, by excluding
males subjected to IPV (in 2012 estimated to be 5.3 % of
Australian males experiencing physical or sexual abuse
since the age of 15 by a partner) [11], we have understated
the potential economic impacts of reducing the prevalence
of IPV.
Several other limitations of the current study must be
acknowledged. Since women are not directly questioned in
the NHS on the issue of IPV, we have relied on surveyed
levels of psychological distress amongst surveyed females
as a proxy. We acknowledge that not all women with
psychological distress, as measured on the Kessler 10, are
IPV victims, and nor are women with psychological dis-
tress confirmed as having psychological conditions. Since
direct evidence was unavailable from the NHS for women
with IPV, we chose to use high psychological distress as a
reasonable proxy, however this may have led to sources of
under- or overestimation, of workforce impacts, since it
remains unclear if women who experience IPV have simi-
lar patterns of psychological distress as women who do
not. The Burden of Disease studies have provided evidence
that depression and anxieties are the largest components
of illness attributable to IPV [36]. For this study, the levels
of depression and anxieties was adequately captured by the
Kessler 10 score used in the NHS [20]. To-date, there
remains a lack of consistent and direct evidence for IPV in
Australia and the ABS has only recently released a national
data framework for enabling a standardized approach to
capturing data on family, domestic and sexual violence, so
in the future more direct evidence may be available for
these studies [37]. Another potential limitation is that we
have not controlled for the presence of other risk factors,
or socioeconomic status, in the analysis and this may be a
source of potential over- or under-estimation of benefits.
We have assumed risk reversibility and risk reduction
arising from absence of current IPV, and that the cross sec-
tional evidence in the NHS related to workforce behaviours
would be associated with a future change in IPV status of
women. Longitudinal cohort data are missing at this point
to confirm our assumptions. Despite these limitations,
we attempted to address such sources of under- or
over-estimation by undertaking detailed sensitivity and
uncertainty analyses.
Conclusions
Investment in disease prevention and health promotion
in Australia is dwarfed by avoidable spending on disease
treatment. The findings of this study contribute important
new knowledge about the major impact of IPV on the
productivity of females in both the paid and unpaid
sectors, as well as health sector expenditure. Our findings
reinforce the argument that greater investment in IPV
reduction strategies is required and economically justified,
particularly in young women. Importantly, our study
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highlights the need for better data in this field so that the
economic impacts can be assessed using direct evidence.
We applaud the ABS and the Australian Government who
have now established a national data framework to address
these methodical issues [38]. While anxiety and depression
represent the greatest proportion of the disease burden
attributable to IPV, women subjected to IPV tend to have
other behavioural risk factors for chronic disease and the
impacts extend to the whole family, in particular children
who can also suffer health impacts from witnessing
IPV. Our findings provide a much needed business case to
support policy makers in addressing this important
societal issue.
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